Sienna Diagnostics Ltd is a Melbourne based biotechnology company, that has developed, and commercialized, a new technology with application in the early detection of cancer. Sienna has proprietary technology it has fully commercialized the first of its numerous applications, with CE-marked (EU), Medicare rebate approved here in Australia, and in the USA they have also have Medicare approval with a $108 rebate per test.  Sequoia (part of the Interprac Group) are handling the Initial Public Offering (IPO) of Sienna at a a competitive valuation and raising up to $6 million at 20 cents per share.

Sienna has built a strong team and a global scientific, clinical, and commercial network. We believe the company has solid management and well credentialed and experienced board.  It has as solid technology and has the potential for a compelling niche in the US market, let alone globally.  The offer is open  until fully subscribed or at the latest 17th July 2017. Further information can be obtained at

For eligibility and suitability within your portfolio, please contact our office MDK Wealth Management (03) 5133 9117


Categories: News

Leave a Reply


    MDK Wealth Management Pty Ltd
    ACN 075 266 250 ABN 19 075 266 250
    Corporate Authorised Rep. No. 342803
  • Licensee

    Corporate Authorised Representative of
    InterPrac Financial Planning Pty Ltd
    AFSL 246638
  • Address

    22 Hazelwood Rd Morwell, VIC 3840

    Level 8, 525 Flinders St, Melbourne VIC 3000
  • Contact

    Tel: (03) 5133 9117
    Fax: (03) 5133 9337